Magnetic Resonance Nanotherapy for Malignant Tumors

2019 ◽  
pp. 197-207
Author(s):  
V. Orel ◽  
A. Shevchenko ◽  
T. Golovko ◽  
O. Ganich ◽  
O. Rihalsky ◽  
...  
Keyword(s):  
Magnetic Resonance ◽  
Malignant Tumors

Preparation of Magnetic Resonance Nano Contrast Agent and Its Adoption in Diagnosis of Breast Cancer

2021 ◽  
Vol 13 (9) ◽  
pp. 1611-1621
Author(s):  
Rong Guo ◽  
Binbin Ma ◽  
Jiaqiu Nie
Keyword(s):  
Breast Cancer ◽  
Differential Diagnosis ◽  
Magnetic Resonance ◽  
Contrast Agent ◽  
Malignant Tumors ◽  
Nipple Discharge ◽  
Mri Contrast Agent ◽  
Cytotoxicity Test ◽  
Mri Contrast ◽  
Magnetic Resonance Imaging Mri

This study aimed to explore the value of preoperative mammography in the differential diagnosis of benign and malignant tumors of nipple discharge. A biocompatible T1 contrast agent KMnF3 nanoparticle was first developed in the research, and then RGD-coupled KMnF3 nanoparticles were further synthesized as a highly sensitive tumor-targeted magnetic resonance imaging (MRI) contrast agent. While the nanoparticle was characterized physically, cytotoxicity test and MRI test in breast cancer mice were performed, and the excised tumors were subjected to immunostaining and tumor electron microscope section processing. At the same time, 60 patients with nipple discharge were screened to participate in the research, and the prepared MRI nano contrast agent was used for the differential diagnosis of breast benign/malignant tumors of nipple discharge. In the experiment, the synthetic nanoparticles were tested by Fourier transformed infrared (FTIR), which proved that the designed RGDtu/KMnF3 nanoparticles were successfully synthesized. The quantitative analysis of the synthesized nanoparticles showed that the relaxation efficiency reached 23.12 mM−1s−1, and there was no obvious toxicity. After staining, the microscope showed that the tumor was proliferating. After intravenous injection of low-dose RGDtu/KMnF3 contrast agent, nanoparticles were found in the tumor tissue. It was found that the synthesized nanoparticles enhanced the contrast of tumors with a volume of less than 50 mm3 by observing tumor slices. The imaging of the patient’s breast showed that the X-ray classification of galactography based on this contrast agent was statistically significant in distinguishing benign/malignant lesions of nipple discharge (X2 = 58.700, P < 0.01).

Retropancreatic Retroperitoneal Tumors: A 30-year Experience with 38 Cases

2013 ◽  
Vol 79 (5) ◽  
pp. 470-475
Author(s):  
Tao-Tao Zhang ◽  
Ke-Jian Guo ◽  
Gang Ma ◽  
Shao-Wei Song
Keyword(s):  
Magnetic Resonance ◽  
Surgical Management ◽  
Malignant Tumors ◽  
Pancreatic Head ◽  
Magnetic Resonance Cholangiopancreatography ◽  
Uncinate Process ◽  
The Body ◽  
Number Of Patients ◽  
Retroperitoneal Tumors

Retropancreatic retroperitoneal tumors (RRTs) are seldom encountered in clinical practice. The lack of characteristics on clinical presentation and imaging make preoperative diagnosis difficult and surgical management remains a challenge. This retrospective report surveys the presenting diagnosis and surgical management of 38 patients with RRTs presenting at our center between August 1981 and May 2012. Six patients were misdiagnosed on the basis of computerized tomography and one each by magnetic resonance imaging and magnetic resonance cholangiopancreatography. Tumors were localized posterior to the pancreatic head and uncinate process (n = 18); posterior to the neck and body of the pancreas (n = 9); or posterior to the body and tail of the pancreas (n = 11). Thirty-three patients underwent surgical resections. Operative approaches were chosen on the basis of tumor size and localization. The tumors were mostly commonly originating from neurogenic tissue (n = 16). There were 25 benign neoplasms (65.8%), 10 malignant tumors (26.3%), and three undefined tumors. The morbidity of postsurgical complications was 21 per cent (eight of 38). The number of patients who underwent follow-up was 21, and the mean follow-up time was 35 months (range, 2 to 90 months). Three patients died during follow-up. The morbility of local recurrence was 10.5 per cent (four of 38). Definitive diagnosis of RRTs is made at laparotomy. Complete resection remains the fundamental objective of disease management. Different operative approaches should be used according to tumor localization and size.

scholarly journals The Privilege of Proton Magnetic Resonance Spectroscopy in Evaluating Ovarian Tumors

QJM ◽  
2020 ◽  
Vol 113 (Supplement_1) ◽  
Author(s):  
A A Hafez ◽  
M A Nasr ◽  
N L Salman
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Malignant Tumors ◽  
Radiology Department ◽  
Invasive Technique ◽  
Resonance Spectroscopy ◽  
Ovarian Mass ◽  
University Hospitals ◽  
Non Invasive

Abstract Background Exclusion of malignancy in ovarian mass is of paramount importance. It is the most crucial step after identification of a mass and it has a profound effect on the patient's management. So, a reliable method with which to differentiate a benign from a malignant ovarian mass would provide a basis for optimal preoperative planning and may also reduce the number of unnecessary laparotomies for patients undergoing treatment for benign disease. Objective The aim of our study is to highlight the role of magnetic resonance spectroscopy as a non-invasive technique which may effectively assist in differentiating benign from malignant ovarian masses. Patients and Methods This study included 20 patients with adnexal masses as suggested by preliminary pelvic ultrasound examination. referred from the Gynecology Department to the Radiology Department at Ain shams university hospitals. nine were benign, two were borderline, and six were malignant tumors and 3 were hemorrhagic cyst. Endometriosis, tubo-ovarian abscess. Results Our study revealed sharp choline peak in some benign as well as some malignant cases and so Cho peak could not help in the differential diagnosis between benign and malignant tumors, creatine, lipid and NAA were detected in both benign and malignant tumors, also Choline/Creatine Ratio fairly can differentiate between benign and malignant tumors with cut off point = 3.750 at sensitivity = 75.0% & specificity = 100.0% . Conclusion Our study had some factors that affect the results. First, the sample size were not enough to achieve a good results, second, diversity of samples and the complicated tumor histopathologic and morphologic features.

Low Field Magnetic Resonance Imaging of Focal Hepatic Masses at 0.02 T

1989 ◽  
Vol 30 (6) ◽  
pp. 591-595
Author(s):  
L. Ekelund ◽  
L. Athlin
Keyword(s):  
Magnetic Resonance ◽  
Mr Imaging ◽  
Malignant Tumors ◽  
Signal To Noise Ratio ◽  
Malignant Neoplasms ◽  
Hepatic Hemangioma ◽  
Resonance Imaging ◽  
Benign Lesions ◽  
Low Field ◽  
Better Than

The diagnostic utility of extremely low field magnetic resonance (MR) imaging was evaluated in 25 patients with focal hepatic masses, including 17 with primary (n=7) or secondary (n= 10) malignant neoplasms and 8 with benign lesions (6 hemangiomas). The findings were compared with the results of computed tomography (CT). Out of 16 patients with malignant tumors demonstrated by both modalities, the diagnostic information from MR imaging was equal to or better than that from CT in 6 patients and inferior to CT in 10. Shortcomings of MR were mainly due to low signal-to-noise ratio and poor spatial resolution, resulting in an image quality inferior to that obtained at higher field strengths. Considering these facts, together with the long imaging times required, low field MR cannot be recommended for general use in the evaluation of hepatic masses. On the other hand, our results indicate that this technique may be useful in establishing the diagnosis of hepatic hemangioma.

Localized 31P magnetic resonance spectroscopy of large pediatric brain tumors

1990 ◽  
Vol 72 (1) ◽  
pp. 65-70 ◽  
Author(s):  
Leslie N. Sutton ◽  
Robert E. Lenkinski ◽  
Bruce H. Cohen ◽  
Roger J. Packer ◽  
Robert A. Zimmerman
Keyword(s):  
Magnetic Resonance ◽  
Magnetic Resonance Spectroscopy ◽  
Brain Tumors ◽  
Malignant Tumors ◽  
Benign Tumors ◽  
Resonance Spectroscopy ◽  
Normal Brain ◽  
Content Type ◽  
Metabolic Fingerprint

✓ Fourteen children aged 1 week to 16 years, with a variety of large or superficial brain tumors, underwent localized in vivo 31P magnetic resonance spectroscopy of their tumor. Quantitative spectral analysis was performed by measuring the area under individual peaks using a computer algorithm. In eight patients with histologically benign tumors the spectra were considered to be qualitatively indistinguishable from normal brain. The phosphocreatine/inorganic phosphate ratio (PCr/Pi) averaged 2.0. Five patients had histologically malignant tumors; qualitatively, four of these were considered to have abnormal spectra, showing a decrease in the PCr peak. The PCr/Pi ratio for this group averaged 0.85, which was significantly lower than that seen in the benign tumor group (p < 0.05). No difference between the two groups was seen in adenosine triphosphate or phosphomonoesters. It is concluded that a specific metabolic “fingerprint” for childhood brain tumors may not exist, but that some malignant tumors show a pattern suggestive of ischemia.

Sign in / Sign up

Export Citation Format

Share Document